These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20370676)

  • 1. Leptin: the prototypic adipocytokine and its role in NAFLD.
    Procaccini C; Galgani M; De Rosa V; Carbone F; La Rocca C; Ranucci G; Iorio R; Matarese G
    Curr Pharm Des; 2010 Jun; 16(17):1902-12. PubMed ID: 20370676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis.
    Tilg H
    Curr Pharm Des; 2010 Jun; 16(17):1893-5. PubMed ID: 20370678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy.
    Tsochatzis EA; Papatheodoridis GV; Archimandritis AJ
    Mediators Inflamm; 2009; 2009():831670. PubMed ID: 19753129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.
    Schäffler A; Schölmerich J; Büchler C
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jun; 2(6):273-80. PubMed ID: 16265231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinol-binding protein 4 and new adipocytokines in nonalcoholic fatty liver disease.
    Tönjes A; Blüher M; Stumvoll M
    Curr Pharm Des; 2010 Jun; 16(17):1921-8. PubMed ID: 20370670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.
    Polyzos SA; Kountouras J; Zavos C
    Curr Mol Med; 2009 Apr; 9(3):299-314. PubMed ID: 19355912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk?
    Montecucco F; Mach F
    Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):301-7. PubMed ID: 19075784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant.
    Chen HJ; Liu J
    Biomed Pharmacother; 2018 Jan; 97():1386-1396. PubMed ID: 29156528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adipocytokines and hepatic fibrosis.
    Saxena NK; Anania FA
    Trends Endocrinol Metab; 2015 Mar; 26(3):153-61. PubMed ID: 25656826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future therapeutic strategies in NAFLD.
    Mark N; de Alwis W; Day CP
    Curr Pharm Des; 2010 Jun; 16(17):1958-62. PubMed ID: 20370671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver fibrogenesis and metabolic factors.
    Anty R; Lemoine M
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S10-20. PubMed ID: 21742296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance in nonalcoholic fatty liver disease.
    Bugianesi E; Moscatiello S; Ciaravella MF; Marchesini G
    Curr Pharm Des; 2010 Jun; 16(17):1941-51. PubMed ID: 20370677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease].
    Orlik B; Handzlik G; Olszanecka-Glinianowicz M
    Postepy Hig Med Dosw (Online); 2010 May; 64():212-9. PubMed ID: 20498498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
    Stojsavljević S; Gomerčić Palčić M; Virović Jukić L; Smirčić Duvnjak L; Duvnjak M
    World J Gastroenterol; 2014 Dec; 20(48):18070-91. PubMed ID: 25561778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease.
    Ayonrinde OT; Olynyk JK; Beilin LJ; Mori TA; Pennell CE; de Klerk N; Oddy WH; Shipman P; Adams LA
    Hepatology; 2011 Mar; 53(3):800-9. PubMed ID: 21374659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population.
    Zelber-Sagi S; Ratziu V; Zvibel I; Goldiner I; Blendis L; Morali G; Halpern Z; Oren R
    Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):262-9. PubMed ID: 22246329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Soejima Y; Fukusato T
    World J Gastroenterol; 2012 May; 18(19):2300-8. PubMed ID: 22654421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers in nonalcoholic steatohepatitis.
    Armutcu F; Akyol S; Ucar F; Erdogan S; Akyol O
    Adv Clin Chem; 2013; 61():67-125. PubMed ID: 24015600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin: a key player in obesity related disorders.
    Matsuzawa Y
    Curr Pharm Des; 2010 Jun; 16(17):1896-901. PubMed ID: 20370675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis.
    Shih PH; Shiue SJ; Chen CN; Cheng SW; Lin HY; Wu LW; Wu MS
    Mar Drugs; 2021 Mar; 19(3):. PubMed ID: 33809062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.